{"id":40467,"date":"2002-12-01T12:08:00","date_gmt":"2002-12-01T11:08:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2002\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie"},"modified":"2002-12-01T12:08:00","modified_gmt":"2002-12-01T11:08:00","slug":"ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\/","title":{"rendered":"Ist Captopril besser als Losartan bei Herzinsuffizienz? Die OPTIMAAL-Studie"},"content":{"rendered":"<p>Da\u00df Angiotensin-II-Rezeptor-Antagonisten (ARA) etwa gleich positive Effekte wie ACE-Hemmer (ACEI) bei der Indikation Herzinsuffizienz haben, wird gemeinhin angenommen. Durch aufwendiges Marketing haben es die Hersteller der ARA in den letzten Jahren jedoch verstanden, den ARA sogar eine gewisse \u00dcberlegenheit anzudichten. Diese Legende hat durch die OPTIMAAL-Studie (OPtimal Therapy In Myocardial infarction with the Angiotensin II [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Da\u00df Angiotensin-II-Rezeptor-Antagonisten (ARA) etwa gleich positive Effekte wie ACE-Hemmer (ACEI) bei der Indikation Herzinsuffizienz haben, wird gemeinhin angenommen. Durch aufwendiges Marketing haben es die Hersteller der ARA in den letzten Jahren jedoch verstanden, den ARA sogar eine gewisse \u00dcberlegenheit anzudichten. Diese Legende hat durch die OPTIMAAL-Studie (OPtimal Therapy In Myocardial infarction with the Angiotensin II [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[954,1279,1280,1281,338,339,1282,1283,340,341,4163,342,343,1639,330,1643,6063,345],"class_list":["post-40467","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-ace-hemmer","tag-angiotensin-ii-antagonisten","tag-angiotensin-ii-blocker","tag-angiotensin-ii-inhibitoren","tag-angiotensin-ii-rezeptor-antagonisten","tag-angiotensin-ii-rezeptor-blocker","tag-angiotensin-ii-rezeptor-inhibitoren","tag-at-ii-antagonisten","tag-at-ii-blocker","tag-at-ii-inhibitoren","tag-at-ii-rezeptor-antagonisten","tag-at-ii-rezeptor-blocker","tag-at-ii-rezeptor-inhibitoren","tag-captopril","tag-herzinsuffizienz","tag-losartan","tag-optimaal-studie","tag-sartane"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ist Captopril besser als Losartan bei Herzinsuffizienz? Die OPTIMAAL-Studie - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ist Captopril besser als Losartan bei Herzinsuffizienz? Die OPTIMAAL-Studie - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Da\u00df Angiotensin-II-Rezeptor-Antagonisten (ARA) etwa gleich positive Effekte wie ACE-Hemmer (ACEI) bei der Indikation Herzinsuffizienz haben, wird gemeinhin angenommen. Durch aufwendiges Marketing haben es die Hersteller der ARA in den letzten Jahren jedoch verstanden, den ARA sogar eine gewisse \u00dcberlegenheit anzudichten. Diese Legende hat durch die OPTIMAAL-Studie (OPtimal Therapy In Myocardial infarction with the Angiotensin II [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2002-12-01T11:08:00+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Ist Captopril besser als Losartan bei Herzinsuffizienz? Die OPTIMAAL-Studie\",\"datePublished\":\"2002-12-01T11:08:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\\\/\"},\"wordCount\":398,\"keywords\":[\"ACE-Hemmer\",\"Angiotensin-II-Antagonisten\",\"Angiotensin-II-Blocker\",\"Angiotensin-II-Inhibitoren\",\"Angiotensin-II-Rezeptor-Antagonisten\",\"Angiotensin-II-Rezeptor-Blocker\",\"Angiotensin-II-Rezeptor-Inhibitoren\",\"AT-II-Antagonisten\",\"AT-II-Blocker\",\"AT-II-Inhibitoren\",\"AT-II-Rezeptor-Antagonisten\",\"AT-II-Rezeptor-Blocker\",\"AT-II-Rezeptor-Inhibitoren\",\"Captopril\",\"Herzinsuffizienz\",\"Losartan\",\"OPTIMAAL-Studie\",\"Sartane\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\\\/\",\"name\":\"Ist Captopril besser als Losartan bei Herzinsuffizienz? Die OPTIMAAL-Studie - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"datePublished\":\"2002-12-01T11:08:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ist Captopril besser als Losartan bei Herzinsuffizienz? Die OPTIMAAL-Studie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ist Captopril besser als Losartan bei Herzinsuffizienz? Die OPTIMAAL-Studie - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\/","og_locale":"de_DE","og_type":"article","og_title":"Ist Captopril besser als Losartan bei Herzinsuffizienz? Die OPTIMAAL-Studie - Der Arzneimittelbrief","og_description":"Da\u00df Angiotensin-II-Rezeptor-Antagonisten (ARA) etwa gleich positive Effekte wie ACE-Hemmer (ACEI) bei der Indikation Herzinsuffizienz haben, wird gemeinhin angenommen. Durch aufwendiges Marketing haben es die Hersteller der ARA in den letzten Jahren jedoch verstanden, den ARA sogar eine gewisse \u00dcberlegenheit anzudichten. Diese Legende hat durch die OPTIMAAL-Studie (OPtimal Therapy In Myocardial infarction with the Angiotensin II [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2002-12-01T11:08:00+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Ist Captopril besser als Losartan bei Herzinsuffizienz? Die OPTIMAAL-Studie","datePublished":"2002-12-01T11:08:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\/"},"wordCount":398,"keywords":["ACE-Hemmer","Angiotensin-II-Antagonisten","Angiotensin-II-Blocker","Angiotensin-II-Inhibitoren","Angiotensin-II-Rezeptor-Antagonisten","Angiotensin-II-Rezeptor-Blocker","Angiotensin-II-Rezeptor-Inhibitoren","AT-II-Antagonisten","AT-II-Blocker","AT-II-Inhibitoren","AT-II-Rezeptor-Antagonisten","AT-II-Rezeptor-Blocker","AT-II-Rezeptor-Inhibitoren","Captopril","Herzinsuffizienz","Losartan","OPTIMAAL-Studie","Sartane"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\/","name":"Ist Captopril besser als Losartan bei Herzinsuffizienz? Die OPTIMAAL-Studie - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"datePublished":"2002-12-01T11:08:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/ist-captopril-besser-als-losartan-bei-herzinsuffizienz-die-optimaal-studie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Ist Captopril besser als Losartan bei Herzinsuffizienz? Die OPTIMAAL-Studie"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=40467"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40467\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=40467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=40467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=40467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}